Cargando…
Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer
Resistance to endocrine therapy and CDK4/6 inhibitors, the standard of care (SOC) in estrogen receptor-positive (ER+) breast cancer, greatly reduces patient survival. Therefore, elucidating the mechanisms of sensitivity and resistance to SOC therapy and identifying actionable targets are urgently ne...
Autores principales: | Saatci, Ozge, Cetin, Metin, Uner, Meral, Tokat, Unal Metin, Chatzistamou, Ioulia, Ersan, Pelin Gulizar, Montaudon, Elodie, Akyol, Aytekin, Aksoy, Sercan, Uner, Aysegul, Marangoni, Elisabetta, Sajish, Mathew, Sahin, Ozgur |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620179/ https://www.ncbi.nlm.nih.gov/pubmed/37914699 http://dx.doi.org/10.1038/s41467-023-42736-y |
Ejemplares similares
-
Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification
por: Saatci, Ozge, et al.
Publicado: (2023) -
Reviving immunogenic cell death upon targeting TACC3 enhances T-DM1 response in HER2-positive breast cancer
por: Gedik, Mustafa Emre, et al.
Publicado: (2023) -
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
por: Saatci, Ozge, et al.
Publicado: (2020) -
Evidence for Diverse Prognosis in High-Grade Serous Ovarian Carcinoma: Solid, Pseudoendometrioid, and Transitional-Like; So-Called “SET Morphology” and Progesterone Receptor Status
por: Uner, Halit, et al.
Publicado: (2022) -
Comprehensive clinicopathologic characteristics of intraabdominal neurogenic tumors: Single institution experience
por: Simsek, Cem, et al.
Publicado: (2021)